

GenCore version 4.5
Copyright (c) 1993 - 2000 CompuGen Ltd.

Run on: June 18, 2001, 15:31:56 ; Search time 50.45 Seconds
(without alignments)
242.476 Million cell updates/sec

Title: US-09-653-755A-5
Perfect score: 1121
Sequence: 1 ENVLTQSPAIMSASPGERKTV.....EATHRTSISPIVKSFNRNEC 214

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 390729 seqs, 57163235 residues

Total number of hits satisfying chosen parameters: 390729

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%,
Maximum Match 100%,
Listing first 45 summaries

Database :

A_Genesed_0401:*

1: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1980.DAT:*

2: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1981.DAT:*

3: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1982.DAT:*

4: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1983.DAT:*

5: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1984.DAT:*

6: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1985.DAT:*

7: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1986.DAT:*

8: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1987.DAT:*

9: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1988.DAT:*

10: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1989.DAT:*

11: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1990.DAT:*

12: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1991.DAT:*

13: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1992.DAT:*

14: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1993.DAT:*

15: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1994.DAT:*

16: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1995.DAT:*

17: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1996.DAT:*

18: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1997.DAT:*

19: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1998.DAT:*

20: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA1999.DAT:*

21: /SIDS6/gcgdata/genesed/geneseq/geneseq/AA2000.DAT:*

22: /SIDS6/gcgdata/genesed/geneseq/AA2001.DAT:*

Pred. No. 1 is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	1084.5	96.7	215	14 R33674
2	1079.5	96.3	215	17 R99644
3	1078.5	96.2	215	17 R9377
4	109.5	90.1	235	17 W06178
5	109.5	90.1	235	20 WB2746
6	1004	89.6	214	17 W15933
7	993.5	88.6	213	10 R93035
8	979.5	87.4	235	12 R13060
9	973.5	86.8	195	11 RD6477
10	950	84.7	208	20 Y44175
11	911	81.3	238	19 WB3042

SUMMARIES

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

Mouse anti-Fas antibody	Murine anti-Fas antibody
MAB 55.1 light chain	MAB 55.1 light chain
MAB 55.1 light chain	MAB 55.1 light chain
MH1 monoclonal antibody	Murine anti-botulinum toxin antibody
Murine anti-botulinum toxin antibody	Murine anti-botulinum toxin antibody
Fab light chain fragment	Antibody 362 light chain
Sequence of the immunogenic region	Fab light chain fragment
Mouse monoclonal antibody	Mouse monoclonal antibody
Mouse antibody F4-35	Mouse antibody FB3
Murine MAB SK48-E2	Kappa anti-carcino
Monoclonal antibody	Monoclonal antibody
L chain subunit of Fas	Anti-human Fas monomer
Anti-human Fas antibody	Anti-human Fas antibody
Fab light chain fragment	WOM-1 Fab light chain
Antibody ABX-CBL 1	WOM-1 Fab light chain
TD9 antibody light chain	TD9 antibody light chain
TD8.12 light chain	TD8.12 light chain
TD8.12 L4-12-1 light chain	TD8.12 L4-12-1 light chain
Amino acid sequence	Amino acid sequence
Mouse immunoglobulin	Mouse immunoglobulin
Porphyrin antibody	Porphyrin antibody
Mouse antibody H3-1	Mouse antibody H3-1
Monoclonal antibody	Monoclonal antibody
Light chain of 59	Light chain of 59
Murine anti-botulinum toxin antibody	Murine anti-botulinum toxin antibody
Anti-tobacco mosaic virus antibody	Anti-tobacco mosaic virus antibody

PA	(ENZO-) ENZON LABS INC.	PR	23-DEC-1994; 94GB-0026192.
PI	Bird RE, Hardman K, Ladner RC;	PA	XX
XX		XX	
WPI:	1996-259060/26.	DC:	Boyle PT, Davies DH, Egglette HJ, Heaton DW;
DR	N-PSDB; T29057.	PI	Blakey DC, Hennequin LFA, Marsham PR, Rabin BR, Slater AM;
DR		PI	Hennain JP, Hennequin LFA, Marsham PR, Rabin BR, Slater AM;
PT	Immunoassay using single chain antigen binding mol. - as replacement for labelled or immobilised antibody, are less immunogenic, easier to engineer, more stable and less expensive	PI	Tarragona-Fiol A, Taylorson CJ;
XX		XX	WPI; 1996-321650/32.
PS	Example 1; Fig 22; 78pp; English.	DR	N-PSDB; T42508.
XX		XX	
XX	Portions of the heavy chain (R97376) and light chain (R97377) of murine IgG1 anti-bovine growth hormone monoclonal antibody 3C2 can be incorporated into novel single polypeptide chain binding molecules (see also W02388-90). These are expressed in host cells using DNA constructs (see also T3460-62) that include heavy and light chain encoding sequences (T29056 and T29057) joined by linker moieties. Following expression and refolding, the single chain binding molecules show the binding characteristics of the aggregate of the 2 original heavy and light chains of the variable region of the antibody.	PT	Two component system for anti-tumour therapy - comprising targeting moiety linked to mutated enzyme which can transform an anti-neoplastic prodrug
CC		PT	XX
CC		PS	XX
CC		Example 6; Page 119-120; 182pp; English.	XX
CC			
CC	A two-component system for anti-tumour therapy comprises a targeting moiety linked to a mutated enzyme which can transform an anti-neoplastic prodrug. The system is based on antibody directed enzyme prodrug therapy (ADEPT) using a non-naturally occurring mutant form of a host enzyme, (Pefc, human pancreatic ribonuclease (HP-RNase), (see T42478-83). The targeting moiety can be an antibody, in partic. murine monoclonal antibody A5B7 (which binds to human carcinoembryonic antigen), A5B7 is suitable for targeting colorectal carcinoma. Fragments, esp. Fab',2, of the antibody can be conjugated to HP-RNase. A5B7 Fc and L chain fragments were isolated by PCR using cDNA isolated from A5B7 hybridoma cells. The present sequence is that of the murine A5B7 L chain.	CC	
CC		CC	XX
CC		CC	
SQ	Sequence 215 AA;	SQ	Sequence 235 AA;
Query Match	96.2%; Score 1078.5; DB 17; Length 215;	Query Match	90.1%; Score 1009.5; DB 17; Length 235;
Best Local Similarity	96.3%; Pred. No. 7.4e-59;	Best Local Similarity	90.2%; Pred. No. 1.3e-54;
Matches	207; Conservative 4; Mismatches 3; Indels 1; Gaps 1;	Matches	194; Conservative 10; Mismatches 8; Indels 3; Gaps 1;
QY	1 ENVLTQSPATMSASPGERTMTCRASSSSSSYIHWYROKSGASPKLWYTSNLASGV 60	QY	1 ENVLTQSPATMSASPGERTMTCRASSSSSSYIHWYROKSGASPKLWYTSNLASGV 60
Db	1 envltqspatmsaspgertmtcrassssssyihwyroksgaspklwyltsnlasgv 60	Db	1 envltqspatmsaspgertmtcrassssssyihwyroksgaspklwyltsnlasgv 60
QY	61 ARFSGGSGSTSYSITISSEADEATYQQYQSY-RFGGGKLEIKRADAAPTYSFP 119	QY	61 ARFSGGSGSTSYSITISSEADEATYQQYQSY-RFGGGKLEIKRADAAPTYSFP 119
Db	1 iarrsgsgsgstsystisseyaedatyyqqyqsgplifgagtkleikradaaptysfp 120	Db	1 iarrsgsgsgstsystisseyaedatyyqqyqsgplifgagtkleikradaaptysfp 120
QY	120 PSSQLTSGASAVCFLNNNYPDQINVKKWIDGSEERQVNLNSWTDQDSKDSVSMSSL 179	QY	120 PSSQLTSGASAVCFLNNNYPDQINVKKWIDGSEERQVNLNSWTDQDSKDSVSMSSL 179
Db	121 psseqltsqsgasvvcflnnfypkdnkvkwidgserqvgvlnswtdqdsksdystysmstl 180	Db	121 psseqltsqsgasvvcflnnfypkdnkvkwidgserqvgvlnswtdqdsksdystysmstl 180
QY	180 TLTKDEYERHNSYCEATHKTSTSPIVKSFNRNEC 214	QY	180 TLTKDEYERHNSYCEATHKTSTSPIVKSFNRNEC 214
Db	181 mltkdeyehnhsyceathktstspivkssfnrc 215	Db	181 mltkdeyehnhsyceathktstspivkssfnrc 215
RESULT	4	RESULT	5
W06178		W06178	
ID	W06178 standard; Protein; 235 AA.	ID	W06178 standard; Protein; 235 AA.
XX		XX	
AC	W06178;	AC	W06178;
XX		XX	
DT	17 FEB-1997 (first entry)	DT	10-MAY-1999 (first entry)
XX		XX	
DE	Murine A5B7 light chain.	DE	Plasmid pBE14/A5B7muVkmucK protein.
XX		XX	
KW	ribonuclease; human; pancreatic; anti-tumour therapy; ADEPT;	KW	Conjugate; cell targeting; cytotoxic drug; Plasmid; fusion protein;
KW	mustard-ribonucleotide; antibody directed enzyme prodrug therapy;	KW	prodrug-converting enzyme; cell surface antigen; treatment; cancer;
KW	anti-neoplastic; prodrug; reverse polarity; Ion pair interaction;	KW	inflammation; rheumatoid arthritis; antibody; prodrug therapy system.
KW	reduced immunogenicity; non-selective triggering; primer;	XX	
KW	polymerase chain reaction; PCR; HP-RNase; Fc; F(ab')2.	OS	Synthetic.
OS	Synthetic.	OS	
PN	W0620011-A1.	PN	MuV kmucK
XX		XX	
PD	04-JUL-1996.	PD	Location/Qualifiers
XX		XX	1.22
PF	21-DEC-1995;	PF	Label= signal-peptide
XX		XX	
PR	16-AUG-1995;	PR	95GB-00166810.

XX	OS	XX	XX
XX	Mus.	PN	W0910967-A.
KW	KS1/4; chimeric antibody; light chain variable region;	PN	W0910968-A.
XX		XX	
AC	EP38767-A.	PD	11-JUL-1991.
XX		XX	
DT	25-APR-1989.	PF	21-DEC-1990;
DE		XX	90WO-GB02017.
XX		PR	21-DEC-1990;
FT	18-APR-1989; 89EP-0303814.	PR	89GB-0028874.
XX		XX	
PR	21-APR-1988; 88US-0184522.	PA	(CELL) CELITECH LTD.
XX		XX	
PA	(ELIL) ELI LILLY AND CO.	PI	Adair JR, Athwal DS, Emtage JS;
XX		XX	
PI	Beavers LS, Bumol TF, Gadski RA, Weigel BJ;	DR	WPI; 1999-311203/43.
XX		XX	
DR	DR	XX	N-PSDB; N91657.
XX		PT	Recombinant DNA cpds. producing antibodies - monoclonal and
PT	chimeric derived from monoclonal antibody KS1/4.	PT	chimeric derived from monoclonal antibody KS1/4.
XX		PS	Claim 1; page 49; 89pp; English.
XX		XX	The sequence encodes the light chain of MAB KS1/4, used to
CC	construct mouse/human chimeric antibodies. KS1/4 is a murine antibody	CC	which binds to surface antigens on adenocarcinoma cells and the use of
CC	human C regions avoids immunological problems during treatment.	CC	human C regions avoids immunological problems during treatment.
XX		SQ	Sequence 213 AA;
Query	Match	88.6%; Score 993.5; DB 10; length 213;	
Best	Local Similarity	90.6%; Pred. No. 1.e-53;	
Matches	193; Conservative	7; Mismatches 10; Indels 3; Gaps 2;	
QY	3	VLTQSPAIMSASPGEKVTMCRASSVSSSYLHWYRQKGASPLKWLYSTSNLASGVPAR	62
Db	3	ltlqspalmiasaspgekvtmctcasssv--symwyqkpgsspkpwiftdtsnlasgfar	60
QY	63	FSSSGSGSGLSYLSLTSSVEADAAYYCQSGYR-TREGGTKELEIKRADAAPVSIIFPS	121
Db	61	fsgsgsgtssyslissmaedaatyychqrsqyptfoggtkleikradaapvsiifps	120
QY	122	SEQITSGGASAVCWLNNFPRDINKWKIDSERQNGVLNSWTDQDSKSTDTSMSSTIL	181
Db	121	seqitsggsgasvvcflnnfprdkdnvkwkdgserqngyvinswtdqdskstdtsmsstil	180
QY	182	TKDDEYERHNNSYTCATHKUSTSIVKSFNRNEC	214
Db	181	tkdeyerhnnsytcathktstspivksfnrec	213
RESULT	8	Sequence 235 AA;	
R13060	ID	Query Match 87.4%; Score 979.5; DB 12; Length 235;	
XX	ID	Best Local Similarity 89.2%; Pred. No. 8.4e-53;	
XX	ID	Matches 190; Conservative 6; Mismatches 14; Indels 3; Gaps 2;	
AC	R13060;	QY	3
XX	03-OCT-1991 (first entry)	Db	25
DE	Monoclonal antibody OK3T light chain.	QY	63
XX	OK3T; light chain; humanised antibodies; CDR-grafting.	Db	83
XX	Mus musculus.	QY	122
OS		Db	143
XX		QY	182
FH	Key	Db	203
FT	Peptide	XX	TKDDEYERHNNSYTCATHKUSTSIVKSFNRNEC
FT	Protein	XX	214
FT		XX	tkdeyerhnnsytcathktstspivksfnrec
XX		XX	235
RESULT	9	Sequence 195 AA.	
R06477	ID	Query Match 87.4%; Score 979.5; DB 12; Length 235;	
XX	ID	Best Local Similarity 89.2%; Pred. No. 8.4e-53;	
XX	ID	Matches 190; Conservative 6; Mismatches 14; Indels 3; Gaps 2;	
AC	R06477;	QY	3
XX	07-JAN-1991 (first entry)	Db	25
DE	Light chain of anti-bovine growth hormone Mab.	XX	07-JAN-1991 (first entry)
XX	Monoclonal antibody.	XX	
XX	Mus musculus.	OS	
XX		XX	
FH	Key	XX	US4946778-A.
FT	Peptide	XX	
FT	1.22	PD	07-AUG-1990.
FT	/label= signal peptide	XX	19-JAN-1989; 89US-0299617.
FT	23 .235	XX	
FT	/label= light chain	XX	

PR 19-JAN-1989; 89US-0299617.
 PR 02-SEP-1986; 86US-0902971.
 PR XX
 XX 02-SEP-1987; 87US-0092110.
 PA (GENE-) GENEX CORP.
 PA XX
 PT Ladner RC, Bird RE, Hardman K;
 XX PI
 DR WPI; 1990-260350/34.
 XX N-PSDB; Q05709.
 PT Single polypeptide chain binding molecules - having light chain
 PT variable region of antibody linked by peptide to heavy chain
 PT variable region.
 PS Disclosure; Fig 22; 68pp; English.
 XX
 CC The Mab is produced by the cell line 3C2. It is an IgG1 with a
 CC gamma 1 heavy chain and kappa light chain. The sequence was used
 CC to produce single chain binding molecules comprising the variable
 CC regions of heavy and light chains linked by a peptide. The
 CC variable region of the sequence was prep by introducing a ClaI
 CC site and an initiation codon (atcgat) prior to the first codon of
 CC the mature sequence and a HindIII site and termination codon
 CC (taacctt) after codon 109. The plasmid constructed to contain
 CC this portion was PGK373. A typical polypeptide construction is:
 CC Met-[LCVR(1-41)]-I-A-K-A-F-K-[HCVR(8-105)]-P-G-S-[LCVR(45-109)].
 CC This construction is designated TRY40 (see Q05710, R06478).
 CC See also R06476-84.
 XX
 SQ Sequence 195 AA:
 Query Match 86.8%; Score 973.5; DB 11; Length 195;
 Best Local Similarity 88.8%; Pred. No. 1.6e-52;
 Matches 190; Conservative 4; Mismatches 1; Indels 19; Gaps 1;
 CC
 Qy 1 ENVLVQSPAIMSASPGKEVKVIMCRASSVSSSYLHWYRQKGASKPLWVYSTNLSAGVP 60
 Db 1 envlvtqspainsaspgkevmtcrassvsssylywfgqksgaspklwylstnslasgvp 60
 CC
 Qy 61 ARFSSGGSGSISYSLTISVVERADAATYQCOQYSGRTFGGGTKLEIKRADAAPTVSIFPP 120
 Db 61 arfsqsgsgsystlsvea-----gtkpelkraadaptsifpp 101
 CC
 Qy 121 SSEQIJSNSGGASVWCVLNFYPRDINKWKIDGSERONGVNLNSWTDQSKDSTYSMSSTL 180
 Db 102 sseqqtsggasvvcfinnfpkdinvkwdgseqnqgvlnswtdqskdostysmsstl 161
 CC
 Qy 181 LTKDEYERHNSYTCATHKTSSTSPIVKSFNNEC 214
 Db 162 ltkdeyernhsytceathktstspivksfn 195
 CC
 XX
 SQ Sequence 208 AA:
 Query Match 84.7%; Score 950; DB 20; Length 208;
 Best Local Similarity 88.1%; Pred. No. 4.6e-51;
 Matches 185; Conservative 9; Mismatches 14; Indels 2; Gaps 1;
 CC
 Qy 1 ENVLVQSPAIMSASPGKEVKVIMCRASSVSSSYLHWYRQKGASKPLWVYSTNLSAGVP 60
 Db 1 envlvtqspaitaasqgkvltcasssv-s-symhwyyqksgtspkpwlyeikslasgvp 58
 CC
 Qy 61 ARFSSGGSGSISYSLTISVVERADAATYQCOQYSGRTFGGGTKLEIKRADAAPTVSIFPP 120
 Db 59 arfsqsgsgsystlsmeadaaiyyccqwnyptfsgtkleikradaaptsifpp 118
 CC
 Qy 121 SSEQIJSNSGGASVWCVLNFYPRDINKWKIDGSERONGVNLNSWTDQSKDSTYSMSSTL 180
 Db 119 sseqqtsggasvvcfinnfpkdinvkwdgseqnqgvlnswtdqskdostysmsstl 178
 CC
 Qy 181 LTKDEYERHNSYTCATHKTSSTSPIVKSFN 210
 Db 179 ltkdeyernhsytceathktstspivksfn 208
 CC
 RESULT 10
 Y44175
 ID Y44175 standard; Protein: 208 AA.
 XX
 AC Y44175;
 XX
 DT 01-FEB-2000 (first entry)
 XX
 DE Mab Fab13B5 light chain protein sequence.
 XX
 KW Peptide ligand; affinity; P24; human immune deficiency virus-1; HIV-1;
 KW light chain; heavy chain; Fab; monoclonal antibody; hypervariable region;
 KW infection.
 KW
 OS Mus sp.
 XX FR2777285-A1.
 XX
 PD 15-OCT-1999.

RESULT 11
 W83042
 ID W83042 standard; Protein: 238 AA.
 XX
 AC W83042;
 XX
 DT 15-MAR-1999 (first entry)
 DE Anti Fas Mab HFE7A light chain.
 XX
 KW HFE7A; monoclonal antibody; mouse; Fas; humanised antibody;
 KW apoptosis; HFE7A; autoimmune disease; Hashimoto's disease;
 KW systemic lupus erythematosus; graft versus host disease;
 KW sjogren syndrome; pernicious anaemia; addison's disease;
 KW scleroderma; Goodpasture syndrome; Crohn's disease; sterility;
 KW rheumatoid arthritis; autoimmune haemolytic anaemia;
 KW myasthenia gravis; multiple sclerosis; Basedow's disease;
 KW thrombopenia purpura; insulin dependent diabetes; allergy;
 KW atopy; arteriosclerosis; myocarditis; cardiomopathy;

Sequence	238 AA:
Query Match	81.3%; Score 911; DB 21; Length 238;
Best Local Similarity	81.0%; Pred. No. 1.2e-48;
Matches	175; Conservative 16; Mismatches 21; Indels 4; Gaps 2;
XX	apoptosis in cells with a normal system, by inhibiting binding between Fas and its ligand. The products of the invention have anti-inflammatory, anti-anemic, antidiabetic, anti-allergic, anti-arthritis, antiviral, immunomodulatory, dermatological, immunosuppressive, neuroprotective, anti-hemostatic, nephrotoxic, antiinfective, thymomimetic, antiarrhythmic, claudicant and hepatotoxic activity. (I) induce apoptosis by binding to cell surface Fas or inhibit it by competitive inhibition of ligand binding. (II) are used to treat and/or prevent diseases associated with the Fas/Fas ligand system, especially systemic lupus erythematosus, Hashimoto disease, rheumatoid arthritis, graft versus host disease, Sjögren's syndrome, Pernicious or hypoplastic anemia, Addison's disease, scleroderma, Goodpasture syndrome, Crohn's disease, autoimmune hemolytic anemia, sterility, myasthenia gravis, multiple sclerosis, Bæsodow's disease, thrombopenia purpura, insulin dependent diabetes mellitus, allergy, arteriosclerosis, myocarditis, cardiomyopathy, glomerulonephritis, hepatitis (fulminant, chronic, viral (B, C or D) or alcoholic), and transplant rejection. (II) selectively inhibit apoptosis in normal cells but selectively induce it in abnormal cells. They bind to both human and murine Fas, so can be evaluated in murine disease models. (I) act on the active site of Fas, i.e. they mimic the native ligand, do not induce liver disease, and have reduced risk of inducing a human anti-murine antibody response. This sequence represents a murine anti-Fas monoclonal antibody HFE7A light chain described in the method of the invention.
RESULT	13
W90898	XX
ID	W90898 standard; Protein; 238 AA.
XX	AC W90898;
XX	DT 08-AUG-2000 (first entry)
XX	DE Murine anti-Fas antibody HFE7A light chain protein.
XX	KW Fas; antibody; murine; anti-inflammatory; anti-anemic; antidiabetic; anti-allergic; anti-arthritic; antiviral; immunomodulatory; cardiotant; dermatological; immunosuppressive; thyromimetic; antirheumatic; hepatotropic; antiinfertility; neuroprotective; antiatherosclerotic; hepatotropic; humanized; apoptosis; systemic lupus erythematosus; HFE7A; Hashimoto disease; rheumatoid arthritis; graft versus host disease; Sjögren's syndrome; anemia; Addison's disease; scleroderma; sterility; Goodpasture syndrome; Crohn's disease; myasthenia gravis; multiple sclerosis; Basedow's disease; thrombopenia purpura; allergy; KW insulin dependent diabetes mellitus; arteriosclerosis; myocarditis; cardiomyopathy; glomerulonephritis; hepatitis; transplant rejection. KW OS mus musculus.
XX	PN EP990663-A2.
XX	05-APR-2000.
XX	29-SEP-1999; 99EP-0307711.
XX	PR 30-SEP-1998; 98JP-0276881.
XX	30-SEP-1998; 98JP-0276882.
XX	PA (SANYO) SANKYO CO LTD.
XX	PA Serizawa N, Haruyama H, Nakahara K, Tamaki I, Takahashi T, DR N-PSDB; A11547.
XX	PT Serizawa N, Haruyama H, Nakahara K, Tamaki I, Takahashi T, DR N-PSDB; A11547.
XX	PT New humanized anti-Fas antibody, useful for treating or preventing e.g. inflammatory or autoimmune disease, induces apoptosis selectively in cells with abnormal Fas-Fas ligand systems.
XX	PT Example reference 4; Page 104; 263PP; English.
PS	CC this invention describes a novel humanized anti-Fas antibody-like molecule (I) that, induces apoptosis in cells with an abnormal Fas/Fas ligand system, by binding to Fas on the cell surface, and prevents
XX	CC apoptosis in cells with a normal system, by inhibiting binding between Fas and its ligand. The products of the invention have anti-inflammatory, anti-anemic, antidiabetic, anti-allergic, anti-arthritis, antiviral, immunomodulatory, dermatological, immunosuppressive, neuroprotective, anti-hemostatic, nephrotoxic, antiinfective, thymomimetic, antiarrhythmic, claudicant and hepatotoxic activity. (I) induce apoptosis by binding to cell surface Fas or inhibit it by competitive inhibition of ligand binding. (II) are used to treat and/or prevent diseases associated with the Fas/Fas ligand system, especially systemic lupus erythematosus, Hashimoto disease, rheumatoid arthritis, graft versus host disease, Sjögren's syndrome, Pernicious or hypoplastic anemia, Addison's disease, scleroderma, Goodpasture syndrome, Crohn's disease, autoimmune hemolytic anemia, sterility, myasthenia gravis, multiple sclerosis, Bæsodow's disease, thrombopenia purpura, insulin dependent diabetes mellitus, allergy, arteriosclerosis, myocarditis, cardiomyopathy, glomerulonephritis, hepatitis (fulminant, chronic, viral (B, C or D) or alcoholic), and transplant rejection. (II) selectively inhibit apoptosis in normal cells but selectively induce it in abnormal cells. They bind to both human and murine Fas, so can be evaluated in murine disease models. (I) act on the active site of Fas, i.e. they mimic the native ligand, do not induce liver disease, and have reduced risk of inducing a human anti-murine antibody response. This sequence represents a murine anti-Fas monoclonal antibody HFE7A light chain described in the method of the invention.
XX	Sequence 238 AA:
Query Match	81.3%; Score 911; DB 21; Length 238;
Best Local Similarity	81.0%; Pred. No. 1.2e-48;
Matches	175; Conservative 16; Mismatches 21; Indels 4; Gaps 2;
XX	apoptosis in cells with a normal system, by inhibiting binding between Fas and its ligand. The products of the invention have anti-inflammatory, anti-anemic, antidiabetic, anti-allergic, anti-arthritis, antiviral, immunomodulatory, dermatological, immunosuppressive, neuroprotective, anti-hemostatic, nephrotoxic, antiinfective, thymomimetic, antiarrhythmic, claudicant and hepatotoxic activity. (I) induce apoptosis by binding to cell surface Fas or inhibit it by competitive inhibition of ligand binding. (II) are used to treat and/or prevent diseases associated with the Fas/Fas ligand system, especially systemic lupus erythematosus, Hashimoto disease, rheumatoid arthritis, graft versus host disease, Sjögren's syndrome, Pernicious or hypoplastic anemia, Addison's disease, scleroderma, Goodpasture syndrome, Crohn's disease, autoimmune hemolytic anemia, sterility, myasthenia gravis, multiple sclerosis, Bæsodow's disease, thrombopenia purpura, insulin dependent diabetes mellitus, allergy, arteriosclerosis, myocarditis, cardiomyopathy, glomerulonephritis, hepatitis (fulminant, chronic, viral (B, C or D) or alcoholic), and transplant rejection. (II) selectively inhibit apoptosis in normal cells but selectively induce it in abnormal cells. They bind to both human and murine Fas, so can be evaluated in murine disease models. (I) act on the active site of Fas, i.e. they mimic the native ligand, do not induce liver disease, and have reduced risk of inducing a human anti-murine antibody response. This sequence represents a murine anti-Fas monoclonal antibody HFE7A light chain described in the method of the invention.
RESULT	14
R76086	XX
ID	R76086 standard; Peptide; 219 AA.
XX	AC R76086;
XX	DT 21-NOV-1995 (first entry)
XX	DE Mab 55.1 light chain.
XX	KW Antigen binding structure; complementarity determining region; CDR; KW CDR5.1; colorectal cancer; tumor-associated antigen; hybridoma; KW monoclonal antibody; MAb; immunotherapy; therapy; diagnosis; KW transgenic animal; transgenic plant; antibody engineering; KW humanized antibody; immunotoxin.
XX	OS Mus' sp.
PN	W09515382-A.
XX	PD 08-JUN-1995.
XX	PF 29-NOV-1994; 94WO-GB02610.

Tue Jun 19 08:18:10 2001

us-09-653-755a-5.rag